Abstract Library

#1203 Atypical Bronchial Carcinoid: Different Therapeutical Approachs

Introduction: Choosing an adequate treatment for atypical bronchial carcinoid can improve quality of life and survival.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Geraldo Roig L,

Keywords: 68GaDOTATOC PET-CT, neuroendocrine tumor, atypical bronchial carcinoid, octreotide, PRRT,

#1154 Selective Internal Radiation Therapy (SIRT) Radioembolisation with 90 Yttrium in Patients with Unresectable Liver Neuroendocrine Metastases in a Specialized Center. An Initial Report

Introduction: Most patients with neuroendocrine tumors present liver metastases at some point of the clinical course. Liver directed treatment, such as 90 Yttrium is a method of treatment used in patients with non-resectable liver lesions, which is effective in the control of symptoms and tumor growth.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: García Mónaco R

Authors: García Mónaco R, Peralta O, O'Connor J, Pesce V, Bestani C,

Keywords: 90Yttrium, radioembolization, neuroendocrine tumors ,

#768 Long-Term Haematological and Renal Toxicity of 90Yttrium-DOTA-Octreotate in the Treatment of Advanced Neuroendocrine Tumors(NETs)

Introduction: Peptide receptor radiation therapy (PRRT) is an established treatment for advanced NETs. Renal/haematological toxicity are recognised adverse effects.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MELVILLE A

Authors: Melville A, Cheung V, Garcia-Hernandez J, Pericleous M, Navalkissoor S,

Keywords: NET, PRRT, renal toxicity, bone marrow toxicity, Yttrium90,

#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas

Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Grozinsky-Glasberg S, Barak D, Fraenkel M, Müeller J, Shimon I,

Keywords: PRRT, malignant gastrinoma, treatment, anti-tumor effect ,